Long-Duration Stimulant Treatment Study of ADHD in Young Children

Attention Deficit Disorder With Hyperactivity Clinical Trial

— B-MPH  

Official title:

Long-Duration Stimulant Treatment of ADHD in Young Children-Feasibility Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00257725
• Other study ID #: 4939
• Status: Completed
• Phase: Phase 4
• Start date: March 2005
• Est. completion date: March 2008

Study information

• Verified date: August 2020
• Source: New York State Psychiatric Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate if Ritalin LA™ is safe and effective for ADHD treatment in 4-to-5-year olds.

Description:

This is a single site, open-label, four-week feasibility study of long-duration beaded methylphenidate (B-MPH), also known as Ritalin LA™. B-MPH is a FDA-approved medication for children 6 years and older with attention-deficit/hyperactivity disorder (ADHD), but there are no studies of its use in preschoolers. This study will evaluate the safety and effectiveness of B-MPH for ADHD treatment in 4-to-5-year old children.

Total study duration is approximately 5 weeks. It includes a screening evaluation and 4 weeks of B-MPH treatment with doses ranging from 10 to 30 mg (based on the individual tolerability and efficacy). The study doctor will conduct parent-training sessions during the treatment visits.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 11
• Est. completion date: March 2008
• Est. primary completion date: March 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 4 Years to 5 Years

Eligibility

Inclusion Criteria:

1. Parents/guardians and children must speak English and/or Spanish; parents/guardians must sign consent form; children must verbally assent.

2. Boys and girls from 4-5 years old (inclusive) at screening.

3. Children who meet the DSM-IV criteria for a primary diagnosis of ADHD (combined or hyperactive subtype), with symptoms present for at least 9 months.

4. Children who demonstrate adequate need for treatment due to ADHD symptom-severity and clinical impairment.

5. Children with IQ of at least 70 confirmed by valid IQ test.

6. Children who are in educational settings (pre-school, kindergarten, or elementary school program) with at least 8 same-age peers for at least two half days weekly.

7. Parents and children who can attend weekly study visits.

8. Children who are naïve to ADHD medications; received ADHD medications in the past but are not currently treated; or on ADHD medications but finding them inconvenient (due to short duration of action) or not very helpful

Exclusion Criteria:

1. Children and parents/guardians who do not understand or cannot follow necessary instructions; children and parents who are unwilling to comply with study procedures or cooperate with child psychiatrist.

2. Children taking excluded medications.

3. Children with history of intolerance to MPH/stimulant medications or no response to adequate stimulant trials.

4. Children with current adjustment disorder, autism, psychosis, bipolar disorder, significant suicidality, or other psychiatric disorders.

5. Children with history of physical, sexual, or emotional abuse, which lead to a significant impact on the clinical presentation and potentially some ADHD symptoms.

6. Children with screening abnormalities deemed clinically significant by child psychiatrist.

Related Conditions & MeSH terms

• Attention Deficit Disorder With Hyperactivity
• Hyperkinesis

Intervention

Drug:
• B-MPH
Dosage form is a 20 mg capsule to be given once daily in the morning for 30 days

Locations

Country	Name	City	State
United States	New York State Psychiatric Insitute	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
New York State Psychiatric Institute

Country where clinical trial is conducted

United States, 

References & Publications (1)

Maayan L, Paykina N, Fried J, Strauss T, Gugga SS, Greenhill L. The open-label treatment of attention-deficit/hyperactivity disorder in 4- and 5-year-old children with beaded methylphenidate. J Child Adolesc Psychopharmacol. 2009 Apr;19(2):147-53. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Swanson, Nolan, and Pelham Questionnaire (SNAP-IV)	The SNAP-IV Rating Scale is a revision of the Swanson, Nolan and Pelham (SNAP) Questionnaire (Swanson et al, 1983). The SNAP-IV is based on a 0 to 3 rating scale: Not at All = 0, Just A Little = 1, Quite A Bit = 2, and Very Much = 3. Subscale scores on the SNAP-IV are calculated by summing the scores on the items in the subset and dividing by the number of items in the subset. The score for any subset is expressed as the Average Rating-Per-Item, as shown for ratings on the ADHD-Inattentive (ADHD-I) subset.; Sub scale ranges from 0-3. Higher scores mean better outcome. Change score from baseline is reported.	week 5
Primary	Clinical Global Impressions-Severity (CGI-S)	CGI-S is designed to assess severity of illness on a seven-point scale: 1 = normal (not at ll ill) to 7 = among the most extremely ill patients.; Range: 0-7, higher score means worse outcome. Change from baseline is reported.	week 5
Primary	Children's Global Assessment Scale (C-GAS)	Children's Global Assessment Scale (C-GAS) is designed to assess overall functioning across settings. The scale is rated from 1 to 100, with lower scores reflecting poorer adjustment. Change from baseline is reported.	week 5